“We are at a crucial moment in our fight against cancer,” said ESMO President Prof. Jose Baselga. “We have never before made so much progress in our fight to eradicate cancer as a cause of death, and multidisciplinary treatment is a key factor in this success.”
New data presented at the 33rd ESMO Congress, 12-16 September 2008, Stockholm, Sweden also highlight the benefits of combined treatments:
Phase II trial of pazopanib before surgery in early lung cancer
Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, US researchers report. In a phase II trial, 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumor size shrink by up to 85%.
“This is a positive result that will be explored further,” said Prof. Nasser Altorki from Weil Medical College of Cornell University in New York. “To my knowledge, no other results on the effect of angiogenesis inhibitors in early stage operable lung cancer have been published. The results presented here with pazopanib indicate a highly active drug in this setting and further development in lung cancer is underway to fully understand the value of this drug in this disease.”
Chemotherapy, radiotherapy and cetuximab in head and neck cancer
Treating locally advanced head and neck cancers with an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, has shown promise in a phase II trial, Italian researchers report.
Their trial in 45 patients combined chemotherapy with fluorouracil and carboplatin given on weeks 1, 4 and 7 of treatment, with radiotherapy administered daily on weeks 2-3, 5-6 and 8-10. Cetuximab was also added weekly. “Both complete response rate and long-term results compare favorably with the best reported in the literature,” Dr. Marco Merlano from the S. Croce General Hospital in Cuneo reports. 30 patients experienced a skin toxicity that the authors attribute to an interaction between the treatments, and 2 patients died from toxicities, they report.
Zoledronic acid added to adjuvant endocrine therapy prevents breast cancer recurrences
One-third of breast cancer recurrences in pre-menopausal women can be prevented by adding zoldronic acid to treatment with endocrine therapy combined with anastrazole or tamoxifen.
These results, reported for the first time recently, show that “we can positively impact the fate of our cancer patients by influencing the microenvironment of micro-metastases by relatively simple means,” says lead author Prof. Michael Gnant from the Medical University of Vienna.
The study results are included in the ESMO "Oncology Highlights" session in Stockholm. The findings will be expanded with new data from a multivariate analysis of the variables affecting disease-free and recurrence-free survival, Professor Gnant said.
Vanessa Pavinato | alfa
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine